Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

Bernstein analyst Justin Smith maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of p2,610.00. The company’s shares opened today at p1,430.50.

GSK (GSK) plc and Chimagen Biosciences, a privately held biotechnology company, announced an agreement for GSK to acquire CMG1A46, a clinical-stage dual CD19 and CD20-targeted T cell-engager, from ...

GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac heartburn remedy causes cancer. The British drugmaker’s settlement ...

GSK announced positive results from two phase 3 clinical trials evaluating its experimental drug, depemokimab, for chronic rhinosinusitis with nasal polyps affecting 4% of the population.

On Wednesday, the FDA accepted GSK plc’s (NYSE:GSK) marketing application seeking approval for gepotidacin, an investigational, oral antibiotic for adult and adolescent females with ...

GSK plc GSK announced new data from the phase III AReSVi-006 (Adult Respiratory Syncytial Virus) study. The study evaluated the efficacy of a single dose of its respiratory syncytial virus (RSV ...

LONDON — GSK’s once-booming vaccines business met new challenges in the third quarter, as the company lowered sales forecasts for vaccines for the year. Notably, quarterly sales of the ...

Shares in British pharmaceutical giant GSK rose after the company said it resolved a vast majority of lawsuits in the U.S. claiming its discontinued heartburn medicine Zantac caused cancer.

Wave Life Sciences has taken a step toward validating a new modality, becoming the first group to report therapeutic RNA editing in humans. The update on the GSK-partnered prospect sent Wave’s ...